A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation

The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention

“…The CHADS-P2A2RC score was developed recently as a risk prediction model for identifying patients without atrial fibrillation at high risk of a first arterial thromboembolic event. 9) This risk prediction model assigns one point each to congestive heart failure, hypertension, diabetes mellitus, renal disease (estimated glomerular filtration rate <30 mL/min per the Cockcroft-Gault formula and/or renal replacement therapy at the time of screening), age 65–74 years, active smoking, and multi-vessel obstructive coronary artery disease and 2 points each to age ≥75 years and peripheral artery disease. In the present study ( Supplementary Table 2 ), the CHADS-P2A2RC risk score was calculated in each patient based on the clinical parameters at hospital admission, and patients were categorized into low-risk (CHADS-P2A2RC score ≤1), moderate-risk (CHADS-P2A2RC score 2–3), and high-risk (CHADSP2A2RC score ≥4) based on results from the validation study, in which a CHADS-P2A2RC score ≥4 was associated with a particularly high risk of major adverse cardiac events (MACEs) and all-cause death.…”

“…The present study aimed to analyze the risk-benefit profile of P2Y12 inhibitor monotherapy vs. prolonged DAPT in a contemporary PCI population according to the class of ischemic risk stratified using the CHADS-P2A2RC risk score. 9) …”

Cardiovascular risk in patients with and without diabetes presenting with chronic coronary syndrome in 2004–2016

“…IRRs were adjusted for sex, age, hypertension, previous ischemic stroke, peripheral artery disease, smoking, statin treatment, antiplatelet treatment, and oral anticoagulant treatment. Analyses of MACE, ischemic stroke, cardiac death, and all-cause death were additionally adjusted for atrial fibrillation and heart failure [ 21 ]. Patients examined between 2004 and 2006 were used as reference group throughout analyses.…”

Response to ‘Correspondence on ‘Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease” by Jonget al

“…These are age, gender, heart failure, hypertension, diabetes, smoking and most importantly, the presence or absence of CAD. [3][4][5] Further, most of those with CAD were subsequently treated with statins, which reduces the baseline LDL-C levels and modifies the influence of this baseline characteristic. 6 We used statin treatment as a proxy for hypercholesterolaemia in the adjusted multivariate regression analysis.Second, Jong et al 1 raise an interesting question regarding the impact of high-intensity versus low-intensity statins.…”

“…While we do agree with our colleagues that LDL-C is a player in the pathogenesis of coronary artery disease (CAD) and that LDL-C is an independent predictor of cardiovascular events, there are several more important factors that were included. These are age, gender, heart failure, hypertension, diabetes, smoking and most importantly, the presence or absence of CAD 3–5. Further, most of those with CAD were subsequently treated with statins, which reduces the baseline LDL-C levels and modifies the influence of this baseline characteristic 6.…”